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Abstract
Glutathione (GSH) dysregulation at the gene, protein, and functional levels has been observed in schizophrenia patients.
Together with disease-like anomalies in GSH deficit experimental models, it suggests that such redox dysregulation can play a
critical role in altering neuralconnectivity and synchronization, and thus possibly causing schizophrenia symptoms. To determine
whether increased GSH levels would modulate EEG synchronization, N-acetyl-cysteine (NAC), a glutathione precursor, was
administered to patients in a randomized, double-blind, crossover protocol for 60 days, followed by placebo for another 60 days
(or vice versa). We analyzed whole-head topography of the multivariate phase synchronization (MPS) for 128-channel resting-
state EEGs that were recorded at the onset, at the point of crossover, and at the end of the protocol. In this proof of concept
study, the treatment with NAC significantly increased MPS compared to placebo over the left parieto-temporal, the right
temporal,andthe bilateral prefrontalregions. These changeswere robust both at the groupandatthe individual level.Although
MPS increase was observed in the absence of clinical improvement at a group level, it correlated with individual change
estimated by Liddle’s disorganization scale. Therefore, significant changes in EEG synchronization induced by NAC administration
may precede clinically detectable improvement, highlighting its possible utility as a biomarker of treatment efficacy.
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Introduction
Evidence increasingly points to the involvement of oxidative
stress in schizophrenia pathophysiology [1]. In the last few years,
we have shown that a redox dysregulation due to a glutathione
(GSH) synthesis deficit of genetic origin represents one of the
major risk factors for schizophrenia [2]. Indeed, patients suffering
from schizophrenia manifest genetically determined deficits in the
GSH system. Specifically, (i) GSH levels in the brain and
cerebrospinal fluid of patients are decreased [3–5]; (ii) under
oxidative stress conditions, activity of the key GSH synthesizing
enzyme, glutamate cysteine ligase (GCL), and the GSH levels in
patients’ fibroblasts are diminished [6], and (iii) allelic variants of
the GCL modulatory subunit (gclm) [7] and catalytic subunit (gclc)
[6] genes are associated with the disease.
In particular, in two case-control studies, a GAG trinucleotide
with 7, 8, or 9 repeats polymorphism in the gclc gene showed an
association with schizophrenia [6]. This polymorphism has
functional consequences: subjects with the ‘high risk’ genotypes
(8/7, 8/8, 8/9, and 9/9) showed lower GCL activity, gclc protein
expression,and GSHcontent than subjectswith ‘lowrisk’ genotypes
(7/7 and 7/9). Moreover, in pharmacological and knock-
out models, developmental GSH deficit induces morphological,
neurophysiological, and behavioral anomalies analogous to those
reported in schizophrenia patients [8–15].
A developmental dysregulation of GSH synthesis of genetic
origin, when combined with environmental risk factors, which
generate oxidative stress at specific developmental stages, may
affect functional connectivity – in particular, neural synchroniza-
tion ([2], see also the Discussion). This is likely mediated by
hypoactive N-methyl-D-aspartate (NMDA) receptors, impairment
of parvalbumin immunoreactive fast-spiking GABA interneurons,
imbalance between excitatory and inhibitory activity in temporal
and prefrontal cortices, and damage to myelination, resulting in
altered local oscillations and long-range neural synchronization
[2].
The fact that schizophrenia is associated with abnormalities in
neural synchrony is well documented. Abnormal oscillations and/
or distance synchronization are manifested in the resting state [16–
20], perceptual grouping [21], attention [22,23], working memory
[24–26], consciousness [27], and other cognitive/behavioral
responses (for review see [28]). Therefore, the abnormalities of
synchronization might represent a core pathophysiological mech-
anism for psychotic and cognitive disturbances.
In a recent double-blind, randomized, placebo-controlled
multicenter clinical trial, the supplementation of N-acetyl-cysteine
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e29341(NAC), a GSH precursor and an antioxidant, led to the
improvement of the negative symptoms and reduced side effects
of antipsychotics in a cohort of 140 schizophrenia patients [29].
Based on this promising result and on the assumption that
abnormal neural synchronization in schizophrenia is related to
redox dysregulation/oxidative stress, we proposed that NAC may
have a potential effect on EEG synchronization. To support this
hypothesis, we examine in the present proof of concept study the
effects of NAC treatment on the whole-head topography of
multivariate EEG synchronization in a small subgroup of
schizophrenia patients from the Swiss sample of the above
described NAC clinical trial.
Materials and Methods
Clinical Trial Protocol
The supporting CONSORT checklist is available as supporting
information; see Checklist S1. NAC (2 g daily) and placebo were
administered to schizophrenia patients in a double-blind crossover
design. The clinical trial was conducted from November 2003 to
November 2005. One group received NAC for the first 2 months
and then placebo for another period of 2 months, and the other
group received placebo first and then NAC. NAC was purchased
from Zambon (Italy). NAC and placebo capsules were manufac-
tured by DFC Thompson (Sydney, Australia) and re-conditioned
by a pharmacist of the Department of Psychiatry of the Centre
Hospitalier Universitaire Vaudois and University of Lausanne.
EEG recordings were performed at the onset of the protocol
(baseline measurements), at the point of crossover, and at the end
of the study. In keeping with the main trial protocol [29],
psychopathological scales including the Positive and Negative
Symptoms Scale (PANSS) were evaluated every 2 weeks. The
three syndromes including a negative, a positive, and a
disorganization factor have been computed according to Liddle’s
model [30]. A copy of the trial protocol is included in the
Supporting Information; see Protocol S1.
Participants. The CONSORT [31] flowchart of the trial is
reported in Fig. 1. Eleven patients (nine men; two women; aged
31.963.4 years; mean6standard error) meeting DSM-IV criteria
for schizophrenia were recruited from the ambulatory
Schizophrenia Service of the Department of Psychiatry of the
Centre Hospitalier Universitaire Vaudois by an experienced
psychiatrist and a psychologist well trained in Diagnostic
Interview for Genetic Studies. The mean duration of illness was
9.462.5 years. All patients received atypical antipsychotics except
one who was drug-naı ¨ve. The complete demographic and clinical
characteristics of participants were described in [32]. Among the
11 patients, 9 participated in the clinical trial and 8 completed the
entire study, including EEG recordings at crossover and at the end
of the study. The two patients who withdrew from the study
reported that it was too demanding for them. Of the eight patients
who completed the entire study, six were in the group that first
Figure 1. Enrollment, randomization, withdrawals, and completion of the 2 treatment phases (n=11).
doi:10.1371/journal.pone.0029341.g001
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placebo first and then NAC. As reported in [29], no side-effects
due to NAC have been observed. Both patients and investigators
were blinded until the time of analysis, when data pooling
necessitated unblinding. Recruited patients gave fully informed
written consent, and the Ethics Committee of the Faculty of
Biology and Medicine of the University of Lausanne approved all
procedures. All 11 patients underwent the Diagnostic Interview for
Genetic Studies, developed by the NIMH [33,34], and remained
on their usual antipsychotic medication for the duration of the trial
both in terms of type and dose of medication. Recently the effects
of NAC on auditory sensory processing as manifested by mismatch
negativity, a component of auditory evoked potential related to
NMDA receptor function, were studied in this group of patients
[32].
EEG recording and pre-processing. The resting EEGs
were recorded with the 128-channel Geodesic Sensor Net in a
semi-dark room with a low level of environmental noise. To
control the quality of recordings the EEG tracings were constantly
monitored online. The subjects were seated in a comfortable chair
and instructed to stay relaxed and motionless with eyes closed for
3–4 min. All the electrode impedances were kept under 30 kV
[35]. The recordings of vertex-reference EEG were made using a
12-bit analog-to-digital converter, a digitization rate of 1000
samples/s, and a low-pass filter set to 100 Hz. They were further
filtered (FIR, band-pass of 1–70 Hz, notch at 50 Hz) and
segmented into non-overlapping 1 s epochs using NS 4.2
software (EGI Inc., Eugene, OR, USA). Finally, two separate
data sets were obtained for further analysis: one by re-referencing
the data against the common average reference (CAR), and one by
transforming the data into a two-dimensional surface Laplacian
computed via the Current Source Density toolbox [36]. Those two
data sets were the input for two separate synchronization analyzes,
described further.
Artifacts in all channels were edited offline: first, automatically,
based on an absolute voltage threshold (100 mV) and on a
transition threshold of 50 mV (sample to sample), and then on the
basis of a thorough visual inspection. The sensors that recorded
artifactual EEG (.20% of the recording time) were corrected
using the bad channel replacement tool (NS 4.2 EGI, USA).
Furthermore, we excluded the outer-ring sensors because of their
well-known instability. The number of artifact-free epochs entered
into the analysis was 171639 for the NAC condition and 168662
for Placebo condition.
The data were filtered into four EEG frequency bands: theta (3–
7 Hz), alpha (7–13 Hz), beta (13–30 Hz), and gamma (30–48 Hz).
To this end, we applied an FIR filter with no phase-shift [37].
Multivariate phase synchronization. To assess the
interactions among the recorded neuronal pools, we computed a
Multivariate Phase Synchronization (MPS) index, that is, the
modulus of an order parameter of a population of oscillators [38].
MPS is a measure sensitive only to coherence in the phase of
oscillations and not to their amplitude. Specifically, MPS measures
the amount of phase similarity within a population of oscillators.
Consequently, the MPS may be interpreted as the collective
rhythm produced by the population under study. For instance, if
all oscillators move in a single tight clump, MPS is approximately
1 and the population acts like one giant oscillator. If the
oscillations occur incoherently and no macroscopic rhythm is
produced, MPS is approximately 0.
Let w
(i)
t be the sampled phase of oscillator (i) at time t, L the
number of available samples, and N the number of systems under












where j is the imaginary unit. The first sum provides an
instantaneous estimate of the degree of phase similarity. The
second sum averages that over time, thus providing an estimate of
the synchronization during the observed time period. The MPS
was calculated from the pre-processed epoched EEG signals in the
four conventional frequency bands (see previous sub-section). The
signal phase was estimated by means of the Hilbert transform [39].
To assess the whole-head synchronization topography, we
computed the MPS sensor-wise over the cluster of locations
defined by the sensor itself and the surrounding sensors belonging
to its second-order neighborhood [40]. Such a cluster (on average
about 12 cm wide) is shown in Fig. S1 and spans typical distances
of cortico-cortical connectivity [41]. This approach has been
numerically validated and proved to be a robust and easily scalable
multivariate approach, highly sensitive even with a reasonably
small amount of data [42].
The interpretation of surface EEG synchronization is limited
because of its contamination by volume conduction and reference
electrode effects [43]. These unwanted effects can be minimized
with a high-resolution Laplacian, which isolates the source activity
under each sensor [44]. Yet along with volume conduction, a
Laplacian removes genuine synchronization of widely distributed
source regions, which can be captured by CAR EEG. Here we
examined the topography of synchronization based on a
combination of Laplacian and CAR EEG, thus encompassing
both smaller and intermediate spatial scales of EEG dynamics.
To minimize the effects of signal-to-noise ratio variations on
synchronization results, we performed a supplementary analysis of
EEG power and removed from the MPS maps those sensors for
which such effects could be significant (see Text S1).
Statistical inference
Population Inference. Statistical assessment was performed
using the repeated measures one-way ANOVA with two levels
(NAC and Placebo). Statistical inference was performed
independently for each frequency band of interest. The MPS
and Power/Energy estimations that entered into the statistical
analysis were computed for each patient by using a summary
statistic (the median) over values obtained for all epochs belonging
to the same condition. Considering that synchronization and
power/energy values vary over a finite interval and thus cannot
have a Gaussian distribution, we applied a non-parametric
permutation approach. The permutation procedure was refined
according to a repeated measure design [45].
A P-value for each sensor was obtained by performing 5000
permutations, which were identical for each sensor in order to
retain the spatial covariance structure of the data. To get a
statistical significance for the whole map, we controlled for
multiple hypothesis testing by computing false discovery rates
(FDRs) with the BH linear step-up method [46]. As the
computation of each MPS value involved its neighbors, the FDR
at each sensor was estimated from the P-values of the neighboring
sensors. All the reported effects correspond to FDR values less
than 0.05. To highlight the most pronounced effects, we computed
a Cohen index for the size of the effects. Following a conservative
statistical approach, we report only sensors with effect size bigger
than 1 (i.e. the standard deviation of the effect is bigger than its
average value) for CAR EEG, and 0.7 for Laplacian. Finally, we
report only clusters composed of at least three neighboring sensors.
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dropout rate characteristic for a crossover design, we tuned our
analysis to a small sample size not only by using extremely rigorous
and conservative group statistical analysis, but also by applying an
individual level statistics. For each patient, the distribution of the
MPS values upon the available epochs was compared between the
two conditions, NAC and Placebo. To test the null hypothesis of
equal medians, we applied a Wilkoxon rank-sum test. The BH-
based FDR values were verified to be at least ,0.05, and only
sensors significant at population level were kept. Considering that
the clinical effects of NAC were already established in a large-
sample double-blind, randomized, placebo-controlled trial with
140 patients [29], our approach seems to be sufficient for a
neuroimaging description of the probable mechanisms of clinical
improvement in at least a subsample of Schizophrenia patients.
Correlation analysis. To assess whether the synchronization
changes in the patients are related to psychopathological scores,
we analyzed the correlation topography between MPS and
PANSS as well as between MPS and Liddle’s factors [30]. The
correlation maps were computed by estimating the Pearson
correlation coefficient sensor-wise between the MPS contrast and
the corresponding contrast for PANSS and for Liddle’s score. To
determine whether the correlation values were significantly non-
zero, we applied a permutation-based test [47]. The P-values
obtained after performing 5000 permutations were corrected for
multiple comparisons by means of the BH method and considered
significant at FDR,0.05.
Results
The NAC treatment significantly affected EEG synchronization
(Fig. 2). As the head diagrams show, in the CAR EEG, it induced
MPS increase between the sensors clustered over three locations –
namely, the left parieto-temporal (the neighborhood of T5 and P3
locations), the right temporal (the neighborhood of T4), and the
right prefrontal (the neighborhood of Fp2). The left parieto-
temporal cluster was significant across all frequencies, the right
temporal cluster appeared at the theta and beta-gamma
frequencies, while the prefrontal cluster was limited to the alpha
band. For Laplacian, we found MPS increases in these three
locations only for the higher (beta-gamma) EEG frequencies.
Being limited to a small sample, we secured our group-level
findings by considering the individual NAC-induced changes of
EEG synchronization (Fig. 3). As can be seen from this figure, the
MPS increases in the CAR EEG were robust across all the patients
in all the frequency bands, except the theta band in patient P4. In
the Laplacian, the results were more variable; yet, for each
frequency band, the group-significant effects could be tracked at
least in six out of eight patients. It should be noted that a
supplementary analysis of EEG energy showed no significant
effects of the NAC treatment and that the sensors for which the
changes in EEG energy correlated with MPS were outside the
clusters shown in Fig. 2. Furthermore, Fig. 3 shows that the
imbalance in the number of patients receiving Placebo or NAC
first did not affect our findings. Indeed, patients P2 and P5, which
received Placebo earlier than NAC, demonstrate responses similar
to the average one (Fig. 2). Furthermore, since the majority of the
patients received NAC treatment prior to Placebo, any carryover
effects would have reduced the difference in synchronization
between the two treatment types. The fact that the effect of NAC
nonetheless withstands this sequence argues against a strong
influence of treatment order.
A correlation analysis allowed us to look at the relationship
between EEG synchronization and the psychopathological scores
Figure 2. NAC vs. Placebo changes in population multivariate EEG synchronization. The whole-head maps for the MPS show the surface
topography of the NAC vs. Placebo effect. The maps are presented for CAR EEG data (top) and Laplacian data (bottom) for the theta (h), alpha (a), beta
(b), and gamma (c) frequency bands. They are superimposed on the diagrams of the Geodesic 128-channel Sensor Net. The sensors corresponding to
the International 10–20 System are shown with black circles. They are labeled in the upper left diagram. The large circles (irrespective of color)
designate significant effect. The red sensors correspond to NAC.Placebo. All the effects are shown at FDR,0.05 and the sizes of effects are
thresholded at 1 for CAR EEG and 0.7 for Laplacian. The colored surface (obtained by a trilinear interpolation from the three nearest electrodes)
represents the effect size (see Materials and Methods for details).
doi:10.1371/journal.pone.0029341.g002
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PANSS scores for the contrast NAC vs. Placebo. Since various factor
analytic studies point to the fact that three syndromes (negative,
positive, and disorganization) may underlie schizophrenia symp-
tomatology [48,49], and that the disorganization syndrome is
associated with executive functions and attention [50,51], we also
explored the relationship between EEG synchronization and
Liddle’s scores [30]. We found significant inverse correlations
between Liddle’s factor of disorganization and MPS changes in the
NAC vs. Placebo contrast for the left parieto-temporal cluster at beta
and gamma frequencies (Fig. 4). These correlations show that the
greater the MPS increase, the greater the clinical improvement.
Figure 3. NAC vs. Placebo changes in individual multivariate EEG synchronization. The whole-head maps for the MPS show the surface
topography of the NAC vs. Placebo effect for individual patients. The reported significant changes are restricted to the sensors and frequency bands
that demonstrate a significant effect at the population level (Fig. 1), including four frequency bands for CAR EEG (h, a, b, c) and two frequency bands
for Laplacian (b, c). Patients are labeled as P2, P3, P4, P5, P6, P7, P9 and P13. Other designations are as in Figs. 2 and S1.
doi:10.1371/journal.pone.0029341.g003
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2) was 0.39
for CAR EEG and 0.31 for Laplacian, which means that
synchronization variation can predict or explain 39% and 31%
of Liddle’s score variation, respectively.
Additionally to the findings of NAC effects on EEG synchro-
nization, we provide a description of placebo effects as seen via the
contrast Placebo.Baseline (see Text S1 and Figs. S2, S3 and S4).
Discussion
Our study, through whole-head EEG imaging of multivariate
EEG synchronization, revealed for the first time that NAC, a GSH
precursor, significantly affects EEG synchronization in schizo-
phrenia patients. In so doing, it increases synchronization for three
clusters located over the left parieto-temporal, the right temporal,
and the bilateral prefrontal regions. These changes are manifested
across theta-gamma frequency bands in the CAR EEG but limited
to beta-gamma frequencies in Laplacian, suggesting involvement
of deep sources at slow frequencies and both deep and superficial
sources at fast frequencies [52], which fits current models of EEG
rhythm generation [53–57].
The synchronization changes are robust not only at a group, but
also at an individual level, which, at least partially, compensates
for the limitation imposed by the small size of the sample under
analysis. In other words, the significant individual synchronization
changes confirm the presence of a subgroup of schizophrenia
patients that respond to NAC by changing the landscape of
functional connectivity. Correlations between the treatment-
related dynamics of Liddle’s score for the factor of disorganization
and the synchronization changes in the NAC vs. Placebo contrast for
the left posterior and the bilateral prefrontal clusters further
validate these data. These results are also consistent with reports
on association between the syndrome of disorganization and
defective performance in tasks involving executive functions and
attention as well as language and, possibly, body representation
[50,51].
In the context of a specific pattern of synchronization changes, it
is important to consider that the participants of this study were
among the patients involved in a randomized, double-blind,
placebo controlled, add-on clinical trial, in which the GSH
precursor NAC significantly improved the negative symptoms and
reduced side-effects of antipsychotics [29]. Furthermore, in
roughly the same group of patients (7 out of the 8 analyzed here),
NAC improved the auditory evoked potential by increasing the
NMDA-dependent mismatch negativity [32], which is typically
reduced in schizophrenia [58–60]. On the whole, the EEG/MEG
studies suggest that the temporal and frontal cortices contribute to
generation of mismatch negativity (for recent review see [61]),
which was the case for this group as well [32]. The remarkable
agreement between the topography of mismatch negativity
generators, as shown by the source analysis in the latter study,
and the clusters of NAC-related changes in multivariate
synchronization, revealed here, suggests that functional connec-
tivity plays a role in the central auditory and cognitive dysfunction
underlying the schizophrenia symptoms.
Our findings are in agreement with previous research
emphasizing abnormal functional connectivity in schizophrenia
including resting and task related changes (for review see [62]).
The report of Jalili and collaborators [17] is of special interest
here, since it provides the whole-head landscape of multivariate
synchronization in schizophrenia patients in comparison with
normal subjects. Although that study applied a different measure
Figure 4. Surface topography of correlations between MPS and Liddle’s factor of disorganization for NAC vs. Placebo contrast.
Significant Pearson correlations at FDR,0.05 are shown in the alpha (a) and beta (b) frequency bands for CAR EEG and Laplacian data. Blue circles
designate the sensors with inverse correlations. The size of the correlations is reported as the coefficient of determination defined as the square of
the Pearson correlation value (R
2).
doi:10.1371/journal.pone.0029341.g004
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experimental data show similarity in results obtained with
different estimators of multivariate EEG synchronization (e.g.,
[63]), and, thus, allow a qualitative analysis of the NAC-related
changes in the context of the resting pattern of synchronization in
schizophrenia.
Resting EEG in patients was characterized by bilateral hyper-
synchronized clusters over the temporal lobes and by a hypo-
synchronized cluster over the midline postcentral region [17]. The
individual scores from all the PANSS scales correlated with these
abnormalities such that the greater synchronization changes
(including increase in synchronization) in all the clusters were
linked to the aggravation of pathological symptoms. Furthermore,
their topography was similar to the structural maps of cortical
damage in schizophrenia [64]. Considering the fact that there is
only a partial overlap between the hyper-synchronized temporal
clusters in untreated patients [17] and the regions of increased
synchronization in the NAC-treated patients (here), we can suggest
that NAC is involved in a compensatory response within the
networks with relatively preserved connectivity.
As mentioned in the Introduction, our experimental model has
shown that abnormal connectivity can result from a redox
dysregulation induced by a compromised GSH synthesis. Indeed,
in the hippocampus, GSH deficit results in the alterations of
NMDA-dependent synaptic plasticity through interaction with the
NMDA redox site [13]. Under an oxidative stress, GSH deficit
induces a reduction in beta/gamma-oscillations in the ventral
hippocampus, associated with social and emotional behavioral
anomalies [15]. In the anterior cingulate cortex, transitory GSH
deficit during development leads to decreased spine density [8,65].
Similar findings were reported in schizophrenia patients [66,67].
These abnormalities in anatomical and functional connectivity
are associated with changes in the GABA-ergic fast spiking
parvalbumine interneurons. For example, a reduction in beta/
gamma-oscillations in ventral hippocampus was associated with a
decrease in the number of parvalbumine-immunoreactive GABA
interneurons [15]. In the anterior cingulate of gclm2/2 mice, a
decrease in the power of beta and gamma oscillations was
accompanied by the delayed maturation of parvalbumine
interneurons [68]. This is consistent with the critical role of the
GABA-ergic fast spiking parvalbumine interneurons in the
mechanism of network synchronization [69–73].
A large body of evidence consistently supports the claim that
parvalbumine-immunoreactive GABA interneurons are altered in
schizophrenia [74]. Moreover, converging facts link this alteration
to the hypofunction of NMDA-receptors [75]. Specifically, the
hypofunction of NMDA-receptors leads to the over-production of
free radicals, which can induce the impairment of parvalbumine
interneurons [76,77]. Considering the association between
NMDA-receptors’ hypofunction and GSH deficit, these results
suggest that the GSH precursor NAC can improve synchroniza-
tion dynamics in schizophrenia through interaction with parval-
bumine GABA-ergic connectivity [2].
Indeed, here we observed such effects of NAC on synchroni-
zation after 2 months of treatment, at a time when no significant
amelioration of schizophrenia symptoms was yet detected at a
group level. However, (i) in this group, the Liddle disorganization
factor scores correlated with the individual parieto-temporal
synchronization responses to NAC, which survived rigorous
statistical testing, and (ii) the clinical picture improved in a larger
sample within the frame of a six-month clinical study [29]. In the
case that the results observed in the present proof of concept
study can be reproduced within a larger clinical sample, we
conclude that synchronization dynamics can be more sensitive to
the treatment effects than conventional symptomatology scales
and that it has potential as an early biomarker for treatment
efficacy.
Supporting Information
Figure S1 Example of spatial localization of MPS
estimator. The sensor locations in red exemplify the second
neighborhood for sensor in green (sensor 76) that is the territory
considered in the calculation of a single value of MPS.
(TIF)
Figure S2 Placebo vs. Baseline changes in population
multivariate EEG synchronization. The whole-head maps
for the MPS show the surface topography of the Placebo vs. Baseline
effect in the whole group of schizophrenia patients. The significant
effects were obtained for CAR EEG (top) and Laplacian (bottom)
for the theta (h), alpha (a) and beta (b) frequency bands. They are
superimposed on the diagrams of the Geodesic 128-channel
Sensor Net. The sensors corresponding to the International 10–20
System are shown with black circles. They are labeled in the upper
left diagram. The large circles (irrespective of color) designate
significant effect. The red sensors correspond to Placebo.Baseline,
while the blue sensors correspond to Placebo,Baseline. All the
effects are shown at FDR,0.05. The colored surface (obtained by
a trilinear interpolation from the three nearest electrodes)
represents the effect size (see Materials and Methods for details).
The significant effects are thresholded at an effect size of value
equal to 1.
(TIF)
Figure S3 Placebo vs. Baseline changes in individual
multivariate EEG synchronization. The whole-head maps
for the MPS show the surface topography of the Placebo vs. Baseline
effect for individual patients. The reported significant changes are
restricted to the sensors and frequency bands that demonstrate a
significant effect at the population level (Fig. S1), including three
frequency bands for CAR EEG (h, a, b) and two frequency bands
for Laplacian (h, b). Patients are labeled as P2, P4, P5, P6, P7, P9
and P13. P3 is missing here since baseline recording was of
insufficient quality. Other designations are as in Figs. 2 and S1.
(TIF)
Figure S4 Surface topography of correlations between
MPS and Liddle’s factor of disorganization for Placebo
vs. Baseline contrast. Significant Pearson correlations at
FDR,0.05 obtained in the theta (h) and beta (b) frequency bands
for CAR EEG are shown with large red (for positive correlations)




Text S1 Analysis of EEG energy and effects of placebo
on EEG synchronization.
(DOC)
Protocol S1 Trial protocol 106-03 CE_18-8-03.
(PDF)
Checklist S1 CONSORT checklist.
(DOC)
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